.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Federal Trade Commission
Express Scripts
AstraZeneca
Medtronic
UBS
Cipla
Baxter
Colorcon
Dow

Generated: December 17, 2017

DrugPatentWatch Database Preview

Bionpharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for BIONPHARMA INC, and what generic alternatives to BIONPHARMA INC drugs are available?

BIONPHARMA INC has twenty-three approved drugs.

There are three US patents protecting BIONPHARMA INC drugs.

There are nineteen patent family members on BIONPHARMA INC drugs in seventeen countries and twenty-one supplementary protection certificates in eleven countries.

Summary for Bionpharma Inc

International Patents:19
US Patents:3
Tradenames:24
Ingredients:20
NDAs:23
Drug Master File Entries: 1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bionpharma IncZONISAMIDEzonisamideCAPSULE;ORAL077813-002Aug 16, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Bionpharma IncVITAMIN DergocalciferolCAPSULE;ORAL080704-001Approved Prior to Jan 1, 1982AARXNoNo► Subscribe► Subscribe► Subscribe
Bionpharma IncLOPERAMIDE HYDROCHLORIDEloperamide hydrochlorideCAPSULE;ORAL021855-001Aug 4, 2005OTCYesNo► Subscribe► Subscribe► Subscribe
Bionpharma IncGRANISETRON HYDROCHLORIDEgranisetron hydrochlorideINJECTABLE;INJECTION078863-001Jun 30, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Bionpharma IncNIMODIPINEnimodipineCAPSULE;ORAL076740-001Jan 17, 2008ABRXNoYes► Subscribe► Subscribe► Subscribe
Bionpharma IncMIDOL LIQUID GELSibuprofenCAPSULE;ORAL021472-001Oct 18, 2002OTCYesYes► Subscribe► Subscribe► Subscribe
Bionpharma IncNAPROXEN SODIUMnaproxen sodiumCAPSULE;ORAL021920-001Feb 17, 2006OTCYesYes► Subscribe► SubscribeY► Subscribe
Bionpharma IncPARICALCITOLparicalcitolCAPSULE;ORAL202539-001Mar 27, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Bionpharma IncCALCITRIOLcalcitriolCAPSULE;ORAL091174-002May 24, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Bionpharma IncCETIRIZINE HYDROCHLORIDE ALLERGYcetirizine hydrochlorideCAPSULE;ORAL022429-004Jul 23, 2009OTCYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bionpharma Inc Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006096580► Subscribe
Cyprus1118321► Subscribe
Spain2606767► Subscribe
European Patent Office1863458► Subscribe
European Patent Office3061447► Subscribe
HungaryE030784► Subscribe
Australia7094900► Subscribe
Poland362850► Subscribe
Canada2382292► Subscribe
Mexico2007011039► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bionpharma Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030France► SubscribePRODUCT NAME: DUTASTERIDE; NAT. REGISTRATION NO/DATE: NL 28 131 20030327; FIRST REGISTRATION: SE - 17 871 20020719
2012000051Germany► SubscribePRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
01C/045Belgium► SubscribePRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
00481Netherlands► SubscribePRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
00085Netherlands► SubscribePRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
2012 00035Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
90013-1Sweden► SubscribePRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
C/GB01/041United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
2011005Lithuania► SubscribePRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Citi
QuintilesIMS
Chubb
US Army
UBS
Cerilliant
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot